| RESEARCH PAPER
|Year : 1997 | Volume
| Issue : 6 | Page : 420-425
Clinical evaluation of prazosin in symptomatic benign prostatic hyperplasia ľan Indian experience
S Basalingappa, lgnatius J Xavier, KM Madappa
Objective: To investigate the effectiveness of prazosin, a selective alpha-l adrenoceptor antagonist in the treatment of benign prostatic hyperplasia (BPH) in Indian population.
Methods: Twenty six patients who had obstructive and irritative symptoms in addition to enlarged prostate assessed by Boyarsky symptom score, rectal examination, ultrasonography, uroflowmetry were included. Patients with urinary tract infections, diabetes mellitus, cerebrovascular, cardiovascular diseases and those taking medications known to influence vesicourethral functions were excluded. The patients were administered prazosin (prazopress) 0.5 mg in the morning and 0.5 mg at night in the first week and subsequently, 0.5 mg morning and 1 mg at night for another 3 weeks. Pretreatment and post-treatment assessment criteria were compared statistically using Student's 't' test.
Results: Voiding symptoms, assessed on the basis of Boyarsky scale and micturition history; urinary flow rates measured by uroflowmeter were significantly improved (pc 0.001). Clinical safety was assessed by measurement of blood pressure, volunteered complaints and by questionnaire. At this dosage schedule the clinical safety was good.
Conclusion: Prazosin is effective in the dose of 0.5 mg (morning) and 1 mg (night) in the treatment of patients with symptomatic BPH. The incidence of adverse events related to its vasodilator properties were minimal.
Source of Support: None, Conflict of Interest: None